Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial

ABX464 (Abivax, Paris, France) is a novel, first-in-class, orally administered small molecule for treatment of ulcerative colitis (UC). ABX464 interacts with the cap binding complex, allowing specific splicing of anti-inflammatory miR-124 (microRNA-124), leading to a cascade dextran sulfate sodium of modulating proinflammatory cytokines.1 Additionally, ABX464 demonstrated a dual mechanism of action in HIV—generating miR-124 and splicing viral RNA— warranting further exploration in inflammatory bowel disease.